Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

GEHC vs SYK: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

GEHC Captures Overall Composite Edge (36.0 SELL vs 46.5 HOLD), While SYK Leads 5–1 on Growth & Valuation Pillars

GEHC Overall Winner 6-Pillar Tally: GEHC 1 – 5 SYK Matrix Metrics: GEHC 5 – 5 SYK

As of Nov 16, 2026, GE HealthCare Technologies Inc. (GEHC) captures the overall head-to-head institutional edge over Stryker Corporation (SYK) on higher Unified Composite conviction (36.0/100 SELL vs. 46.5/100 HOLD) after splitting the core matrix 5–5 (led by Valuation Multiples), while SYK wins 5–1 across the 6-pillar growth and valuation breakdown. GEHC trades at $83.19 (15.1x Forward P/E, 13.8% operating margin) versus SYK at $310.79 (19.0x Forward P/E, 24.0% operating margin).

  • Composite vs. Pillar Nuance: While SYK currently prints a higher short-term Unified Composite Score (46.5/100 HOLD vs. GEHC 36.0/100 SELL), GEHC captures the overall institutional head-to-head verdict (5–5 matrix metrics and 1–5 across the 6 pillars) due to superior fundamental profitability (13.8% vs. 24.0% operating margin) and revenue trajectory (+7.2% vs. +7.6% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About GEHC vs SYK
GEHC NASDAQ Head-to-Head Winner
GE HealthCare Technologies Inc. Common Stock
X-Ray Apparatus & Tubes & Related Irradiation Apparatus
$83.19
+0.2% 1D
Market Cap $37.0B
TTM Revenue $21.6B
Forward P/E 15.1x
Beta / 30D Vol 0.53β · 39% Vol
Unified Composite Score
36.0 / 100 SELL
Tech 20.0 Fund 32.0 Flow 58.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (3.3% over 20 days), RSI 69
RSI-14: 68.9 · SMA20: $78.24 · SMA50: $70.84
SYK NYSE
Stryker Corporation
Surgical & Medical Instruments & Apparatus
$310.79
+0.37% 1D
Market Cap $118.9B
TTM Revenue $26.3B
Forward P/E 19.0x
Beta / 30D Vol 0.22β · 50% Vol
Unified Composite Score
46.5 / 100 HOLD
Tech 37.0 Fund 49.0 Flow 58.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 51.5 · SMA20: $312.55 · SMA50: $292.40

6-Pillar Scorecard Institutional Category Breakdown (GEHC 1 – 5 SYK)

Columns: Metric · GEHC · SYK
1. Valuation Multiples GEHC
Forward P/E 15.1x 19.0x
Trailing P/E 17.3x 33.3x
PEG Ratio 2.21x 1.54x
EV / Revenue 2.1x 5.0x
2. Growth & Scale SYK
Revenue Growth (YoY) +7.2% +7.6%
Earnings Growth (YoY) +39.0% -11.7%
TTM Revenue (USD) $21.6B $26.3B
Market Cap $37.0B $118.9B
3. Profitability & Quality SYK
Gross Margin 39.3% 65.7%
Operating Margin 13.8% 24.0%
Net Profit Margin 10.0% 13.8%
Return on Equity (ROE) 20.0% 16.0%
4. Balance Sheet & Cash Flow SYK
Cash Generation (TTM) $1.89B $4.57B
Cash Flow Margin 8.7% 17.4%
Net Cash / Leverage $7.58B Net Debt (0.90x D/E) $11.7B Net Debt (0.64x D/E)
Dividend Yield 0.18% 1.10%
5. Options & Positioning SYK
Options Structure Phase SURGE SURGE
Current IV / %ile 47.7% (6th %ile) 28.1% (5th %ile)
Put/Call OI Skew 0.38x (Call-Skewed) 0.30x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markup DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat SYK
OpEx & R&D Intensity 25.5% of Rev ($5.52B) 41.7% of Rev ($11.0B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Concentrated Oligopoly Moat
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: GEHC (5) vs SYK (5)
Institutional Metric GEHC SYK Criterion Row Edge
Market Capitalization
Scale
$37.0B $118.9B Larger Scale SYK
Trailing P/E Ratio
Valuation
17.3x 33.3x Lower Multiple GEHC
Forward P/E Ratio
Valuation
15.1x 19.0x Lower Multiple GEHC
Revenue Growth (YoY)
Growth
+7.2% +7.6% Higher Growth SYK
Operating Margin (TTM)
Profitability
13.8% 24.0% Higher Margin SYK
Net Profit Margin
Profitability
10.0% 13.8% Higher Margin SYK
Return on Equity (ROE)
Capital Efficiency
20.0% 16.0% Higher ROE GEHC
52-Week Range Position
Momentum
79% ($59–$90) 36% ($267–$389) Stronger Trend GEHC
Beta / 30D Volatility
Risk Regime
0.53β · 39% Vol 0.22β · 50% Vol Lower Realized Risk GEHC
Unified Institutional Score
Composite Signal
36.0 / 100 (SELL) 46.5 / 100 (HOLD) Higher Composite SYK
Trailing 12M Revenue (USD)
Operating Scale
$21.6B $26.3B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
39.3% 65.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
2.21x PEG · 2.1x EV/Rev 1.54x PEG · 5.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$1.89B ($7.58B Net Debt (0.90x D/E)) $4.57B ($11.7B Net Debt (0.64x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon GEHC +14.1 pp
GEHC: +19.57% · SYK: +5.47%
3M Horizon GEHC +20.74 pp
GEHC: +14.53% · SYK: -6.21%
6M Horizon GEHC +36.02 pp
GEHC: +35.24% · SYK: -0.78%
1Y Horizon GEHC +29.23 pp
GEHC: +12.46% · SYK: -16.77%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period GEHC Revenue SYK Revenue GEHC Op. Margin SYK Op. Margin Margin Leader
FY2018 N/A $13.6B N/A 18.7% SYK
FY2019 N/A $14.9B N/A 18.2% SYK
FY2020 N/A $14.3B N/A 15.5% SYK
FY2021 $17.6B $17.1B 15.9% 15.1% GEHC
FY2022 $18.3B $18.4B 13.8% 15.4% SYK
FY2023 $19.6B $20.5B 12.5% 19.0% SYK
FY2024 $19.7B $22.6B 13.3% 16.3% SYK
FY2025 $20.6B $25.1B 13.4% 19.5% SYK

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
GEHC SURGE
8d in phase · OBV DISTRIBUTION
Current IV 47.7%
IV Percentile 6th %ile
Put/Call OI Skew 0.38x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact GEHC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SYK SURGE
8d in phase · OBV DISTRIBUTION
Current IV 28.1%
IV Percentile 5th %ile
Put/Call OI Skew 0.30x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact SYK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
GEHC Moat Profile Scale & Operating Efficiency Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $37.0B market capitalization and 13.8% operating margin.
OpEx & R&D Reinvestment 25.5% of Rev ($5.52B)
90D Engineering Disclosures 0 Published
SYK Moat Profile Concentrated Oligopoly Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $118.9B market capitalization and 24.0% operating margin.
OpEx & R&D Reinvestment 41.7% of Rev ($11.0B)
90D Engineering Disclosures 0 Published · Surgical Robotics

Investor FAQ GEHC vs SYK Key Questions & Quantitative Answers

As of Nov 16, 2026, GE HealthCare Technologies Inc. (GEHC) captures the overall head-to-head institutional edge over Stryker Corporation (SYK) on higher Unified Composite conviction (36.0/100 SELL vs. 46.5/100 HOLD) after splitting the core matrix 5–5 (led by Valuation Multiples), while SYK wins 5–1 across the 6-pillar growth and valuation breakdown. GEHC trades at $83.19 (15.1x Forward P/E, 13.8% operating margin) versus SYK at $310.79 (19.0x Forward P/E, 24.0% operating margin). Composite vs. Pillar Nuance: While SYK currently prints a higher short-term Unified Composite Score (46.5/100 HOLD vs. GEHC 36.0/100 SELL), GEHC captures the overall institutional head-to-head verdict (5–5 matrix metrics and 1–5 across the 6 pillars) due to superior fundamental profitability (13.8% vs. 24.0% operating margin) and revenue trajectory (+7.2% vs. +7.6% YoY).

SYK leads the Growth & Scale pillar: GEHC posts +7.2% YoY revenue growth and +39.0% YoY earnings growth on $21.6B TTM revenue (39.3% gross margin, 13.8% operating margin), compared with SYK at +7.6% YoY revenue growth and -11.7% YoY earnings growth on $26.3B TTM revenue (65.7% gross margin, 24.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), GEHC cumulative revenue shifted +17.2% while SYK shifted +84.7%. In operating R&D and SG&A reinvestment, GEHC deploys 25.5% of Rev ($5.52B) (0 90-day corporate R&D disclosures) versus 41.7% of Rev ($11.0B) (0 disclosures) for SYK.

GEHC screens cheaper on headline valuation multiples. GEHC trades at 15.1x Forward P/E, 17.3x Trailing P/E, 2.21x PEG, and 2.1x EV/Revenue (8.7% FCF margin), whereas SYK trades at 19.0x Forward P/E, 33.3x Trailing P/E, 1.54x PEG, and 5.0x EV/Revenue (17.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GEHC (20.0% ROE) versus SYK (16.0% ROE) capital efficiency.

In options market volatility and institutional positioning, GEHC carries 47.7% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.38x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.53β · 39% Vol realized risk). By comparison, SYK carries 28.1% implied volatility (5th %ile, Compressed (<25th %ile)), a 0.30x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.22β · 50% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.